Back to News
Market Impact: 0.3
Teva To Obtain U.S. Commercialization Rights For Two FDA-approved Immunology Biosimilars
Source: Nasdaq
Healthcare & BiotechProduct Launches
Teva Pharmaceutical Industries and Samsung Bioepis entered into a license and commercialization agreement covering two FDA-approved U.S. immunology biosimilars: infliximab-abda, a biosimilar to Remicade, and ETICOVO, a biosimilar to Enbrel. The article excerpt does not provide further agreement terms or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TEVA0.55
More News
- CrowdStrike's new kill switch can stop rogue AI agents in their tracks, CEO says
- CrowdStrike launches AI kill switch that it says can stop internal agents that go rogue
- iPad mini OLED vs. iPad mini: What's new?
- Midterm elections could jolt stocks if Democrats sweep Congress
- Ferrari’s controversial Luce EV is sold out for 2027
- Reddit tests ads in search results as traffic declines and growth concerns mount